Format

Send to

Choose Destination
See comment in PubMed Commons below
Vascul Pharmacol. 2015 Sep;72:1-8. doi: 10.1016/j.vph.2015.06.011. Epub 2015 Jun 27.

Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease.

Author information

1
Diabetes Research Program, Division of Endocrinology, Department of Medicine, New York University Langone Medical Center, 550 First Avenue, New York, NY 10016, United States. Electronic address: annmarie.schmidt@nyumc.org.

Abstract

Emerging evidence links the receptor for advanced glycation endproducts (RAGE) to the pathogenesis of tissue damage in chronic metabolic and inflammatory diseases. In human subjects, multiple reports suggest that in the plasma/serum, circulating levels of distinct forms of soluble RAGEs may be biomarkers of the presence or absence, and the extent of chronic disease. These considerations prompt us to consider in this review, what are soluble RAGEs; how are they formed; what might be their natural functions; and may they serve as biomarkers of inflammatory and metabolic disease activity? In this brief review, we seek to address what is known and suggest new areas for scientific investigation to uncover the biology of soluble RAGEs.

KEYWORDS:

Soluble RAGE

PMID:
26130225
PMCID:
PMC4547874
DOI:
10.1016/j.vph.2015.06.011
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center